韩国 Biostar 开发的干细胞疗法开始在日本治疗全球帕金森病患者

本文由定制化的企业情报智能服务平台——【情报强企】提供

标签：#cell therpy

韩国首尔2023年11月21日 (Newswire.com) - 韩国领先的成体干细胞研究所Biostar干细胞研究所（所长：Jeongchan Ra博士）20日宣布，开发出治疗帕金森病的再生医学技术通过将利用专利技术培养的自体脂肪干细胞注射到静脉和脊髓腔中的方法已获得日本厚生省的批准，并将于 12 月在东京新宿诊所开始治疗。

SEOUL, South Korea, November 21, 2023 (Newswire.com) - Korea's leading adult stem cell research institute, Biostar Stem Cell Research Institute (Director: Dr. Jeongchan Ra), announced on the 20th that a regenerative medicine technology that treats Parkinson's disease by administering autologous fat-derived stem cells cultured using patented technology into the intravenous and spinal cord cavity has been approved by the Japanese Ministry of Health and Welfare and will begin treatment at the Shinjuku Clinic in Tokyo in December.

批准的干细胞治疗方案包括静脉注射 150 至 2.5 亿个脂肪干细胞，并将 5000 万个细胞注射到脊髓腔中，共注射 5 次，间隔时间为 2 至 4 周。干细胞要么来自韩国 Biostar 干细胞研究所，要么来自日本附属公司 JASC。

The approved stem cell treatment protocol involves administering 150 to 250 million fat-derived stem cells intravenously and 50 million cells into the spinal cord cavity five times at intervals of two to four weeks. The stem cells are either obtained from the Biostar Stem Cell Research Institute in Korea or from JASC, a Japanese affiliate.

干细胞治疗帕金森病的获批标志着映泰干细胞研究所在干细胞临床应用方面的一个重要里程碑，该研究所于2008年开始研究。该研究所此前曾接受过退行性关节炎、严重下肢干细胞治疗缺血和自身免疫性疾病，分别通过关节内、肌肉内和静脉内途径给药。帕金森病干细胞的静脉和脊髓腔给药进一步证明了映泰干细胞培养技术的多功能性和安全性。

The approval of stem cell treatment for Parkinson's disease marks a significant milestone in the clinical application of stem cells by the Biostar Stem Cell Research Institute, which began its research in 2008. The institute has previously received stem cell therapies for degenerative arthritis, severe lower extremity ischemia, and autoimmune diseases, administrated through intraarticular, intramuscular, and intravenous routes, respectively. The intravenous and spinal cord cavity administration of stem cells for Parkinson’s disease further demonstrates the versatility and safety of Biostar’s stem cell culture technology.

根据培养方法的不同，干细胞的安全性和有效性差异很大，凸显了严格质量管理的重要性。映泰干细胞研究所对干细胞培养和治疗技术进行了长达两个十年的研究，包括最近批准的帕金森病疗法，有望开发治疗神经系统疾病的新途径。映泰干细胞研究所开发的专用培养基，由其附属公司Nature Cell独家生产和供应，在提高这些疗法的有效性和安全性方面发挥着至关重要的作用。

Stem cells vary greatly in safety and effectiveness depending on the culture method, highlighting the importance of rigorous quality management. The Biostar Stem Cell Research Institute’s two-decade-long research on stem cell culture and treatment technologies, including the recently approved Parkinson’s disease therapy, holds promise for developing new avenues for treating neurological disorders. The specialized culture media developed by the Biostar Stem Cell Research Institute, exclusively manufactured and supplied by its affiliate Nature Cell, plays a crucial role in enhancing the effectiveness and safety of these therapies.

映泰干细胞研究所致力于在日本各地扩大经批准治疗的医院并加强全球推广，旨在使日本成为全球帕金森病患者恢复健康的目的地。

The Biostar Stem Cell Research Institute is committed to expanding treatment-approved hospitals across Japan and intensifying global outreach, aiming to make Japan a destination for Parkinson's disease patients worldwide to regain their health.

帕金森病估计影响着全世界 1000 万人，其患病率正在迅速增长，并且在没有明确治疗的情况下仍然是一种无法治愈的疾病。

Parkinson’s disease affects an estimated 10 million people worldwide, with a rapidly growing prevalence, and remains an incurable condition without a definitive treatment.

本文内容来源于网络资料，由【情报强企】整理